Ernexa Therapeutics Inc.
Ernexa Therapeutics Inc. (ERNA): ~13 mo cash runway. Updated within the last hour.
BioSniper Score
3-factor signal · derived from public data
12.5 months
D/E 0.54 · 0% dilution
N/A
N/A
N/A
1 buy · 0 sells (180d)
A transparent, data-derived signal for Ernexa Therapeutics Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$6.9M
Cash
$9.2M
Quarterly Burn
$2.3M
Runway
12.5 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Frequently asked questions
What is Ernexa Therapeutics Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Ernexa Therapeutics Inc. has approximately 12.5 months of cash runway.
What is Ernexa Therapeutics Inc.'s market capitalization?
Ernexa Therapeutics Inc.'s market capitalization is approximately $6.9M.
Who is the CEO of Ernexa Therapeutics Inc.?
Mr. Sanjeev Luther is the chief executive officer of Ernexa Therapeutics Inc. (ERNA).
Get the full picture on Ernexa Therapeutics Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.